Eterna Therapeutics Inc Cash Flow Conversion Efficiency
Eterna Therapeutics Inc cash flow conversion efficiency. Based on the latest financial reports, Eterna Therapeutics Inc (ERNA) has a cash flow conversion efficiency ratio of -1.298x as of June 2026. Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow ($-4.15 Million) by net assets ($3.20 Million). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations.
Cash Flow Conversion Efficiency of Eterna Therapeutics Inc (2007–2025)
Cash flow conversion efficiency of Eterna Therapeutics Inc from 2007 to 2025. This chart illustrates how Eterna Therapeutics Inc's cash flow conversion efficiency has evolved over time, based on yearly financial data. View Eterna Therapeutics Inc (ERNA) share price today for real-time trading data and today's change.
Eterna Therapeutics Inc Cash Flow Conversion Ratio Explained
Eterna Therapeutics Inc cash flow conversion ratio divides operating cash flow by net assets, so a higher ratio means more cash generated from each unit of shareholder equity.
Eterna Therapeutics Inc Competitors by Cash Flow Conversion Efficiency
The table below lists competitors of Eterna Therapeutics Inc ranked by their cash flow conversion efficiency. Also see market cap of Eterna Therapeutics Inc for the company's overall valuation and market capitalisation.
| Company | Cash Flow Conversion Efficiency |
|---|---|
|
Zeta Network Group
NASDAQ:ZNB
|
0.014x |
|
Conneqt Health Limited
AU:CQT
|
1.844x |
|
Galeo Concept SA
PA:MLGAL
|
N/A |
|
Alaunos Therapeutics Inc
NASDAQ:TCRT
|
-0.460x |
|
JPMorgan China Growth & Income PLC
LSE:JCGI
|
0.008x |
|
Singularity Future Technology Ltd
NASDAQ:SGLY
|
-0.798x |
|
TECH INVEST GROUP ZY-02
F:6N2
|
0.044x |
|
Nobel29 Resources Corp
V:NBLC
|
0.055x |
Annual Cash Flow Conversion Efficiency for Eterna Therapeutics Inc (2007–2025)
The table below shows the annual cash flow conversion efficiency of Eterna Therapeutics Inc from 2007 to 2025. Review how much free cash does Eterna Therapeutics Inc generate to assess how much free cash flow the company generates relative to operating cash flow.
| Year | Net Assets | Operating Cash Flow | Cash Flow Conversion Efficiency | Change |
|---|---|---|---|---|
| 2025-12-31 | $2.40 Million | $-7.02 Million | -2.923x | +68.61% |
| 2024-12-31 | $1.70 Million | $-15.84 Million | -9.310x | -1.87% |
| 2023-12-31 | $2.23 Million | $-20.41 Million | -9.139x | -427.50% |
| 2022-12-31 | $12.11 Million | $-20.98 Million | -1.733x | -88.13% |
| 2021-12-31 | $25.50 Million | $-23.49 Million | -0.921x | +12.93% |
| 2020-12-31 | $7.66 Million | $-8.10 Million | -1.058x | -296.24% |
| 2019-12-31 | $5.09 Million | $2.74 Million | 0.539x | +173.13% |
| 2018-12-31 | $6.92 Million | $1.36 Million | 0.197x | +98.99% |
| 2017-12-31 | $5.54 Million | $549.00K | 0.099x | +1654.00% |
| 2016-12-31 | $4.07 Million | $23.00K | 0.006x | +100.52% |
| 2015-12-31 | $3.85 Million | $-4.18 Million | -1.086x | -85.85% |
| 2014-12-31 | $10.92 Million | $-6.38 Million | -0.584x | -460.25% |
| 2013-12-31 | $9.20 Million | $1.49 Million | 0.162x | -40.59% |
| 2012-12-31 | $7.89 Million | $2.16 Million | 0.273x | +202.14% |
| 2011-12-31 | $6.35 Million | $574.00K | 0.090x | -69.79% |
| 2010-12-31 | $9.46 Million | $2.83 Million | 0.299x | +12.59% |
| 2009-12-31 | $9.42 Million | $2.50 Million | 0.266x | +100.69% |
| 2007-12-31 | $15.57 Million | $-604.00 Million | -38.798x | -- |
About Eterna Therapeutics Inc
Ernexa Therapeutics Inc., a preclinical-stage company, develops induces derived mesenchymal stem cells (iMSC) therapies for the treatment of treatment of cancer and autoimmune disease. The company's lead product is ERNA-101, an allogenic pro-inflammatory cytokine (IL-7/IL-15) secreting iMSC for the treatment of ovarian cancer; and ERNA-201, an anti-inflammatory cytokine (IL-10) secreting iMSC for… Read more